Amgen highlights durability, seeks biomarkers as response rates slip for KRAS inhibitor AMG 510

Amgen’s leading KRAS inhibitor hasn’t maintained the exceptionally high response rates seen in its earliest readouts, but the first longer-term data for AMG 510 start to answer one of the biggest questions for therapeutics against the target: whether it can produce durable responses. 

At the European Society of Medical Oncology Virtual Congress on Sunday, Amgen Inc. (NASDAQ:AMGN) presented updated data from the Phase I CodeBreaK100 study of sotorasib (AMG 510) showing that the highest dose led to a 35.3% ORR and a 91.2% disease control rate in 34 previously treated non-small cell lung cancer (NSCLC) patients expressing the KRAS G12C mutation. ...